Initially approved for treatment-resistant depression, ketamine's rapid and robust effects in improving mood suggest potential benefits for managing the anxiety, depression, and obsessive thoughts often seen in eating disorders.

CRPS

In conclusion, this research provides valuable insights into the comparative benefits and drawbacks of four augmentative treatments for TRD. For Dr. Danish and his team at Philadelphia Integrative Psychiatry

The study concludes that for IV ketamine, lower doses within the range of 0.2 to 0.5 mg/kg are effective for treatment-resistant depression without additional benefits at higher doses.

By embracing the transformative potential of psychedelic and ketamine-assisted psychotherapies, Philadelphia Integrative Psychiatry is at the forefront of providing comprehensive, personalized treatment plans that address the multifaceted needs of our patients.

Ketamine-Assisted Psychotherapy (KAP) is gaining recognition for its potential to accelerate therapeutic processes in patients by lowering defense mechanisms and enhancing brain plasticity, often referred to as neuroplasticity.

In the realm of mental health, innovative treatments are constantly being explored to offer hope and relief to those suffering from various conditions.

When Dr. Danish first introduced Intravenous (IV) Ketamine as a treatment option for depression in the region, it marked the beginning of a new era in psychiatric care.

Recent discussions have highlighted the potential of ketamine, a drug known for its anesthetic properties, as a promising treatment for mental health disorders, particularly treatment-resistant depression (TRD).

When Dr. Danish first introduced Intravenous (IV) Ketamine as a treatment option for depression in the region, it marked the beginning of a new era in psychiatric care.